Charles Kaplan is Bitterroot Bio’s Senior Vice President of Research. He has more than 20 years of drug discovery and development experience and has led programs from early discovery through early Phase 1 trials.
Dr. Derek Klarin is Executive Director of Genomic Medicine & Data Science at Bitterroot Bio. His research has applied genomic approaches to vascular disease and associated risk factors, including lipids and thrombosis.
Julie (Ju Yun) Son is Director and Corporate Counsel at Bitterroot Bio. Grounded in both science and law, she brings technical fluency to complex life sciences transactions — advising on strategic licensing and collaborations, clinical and regulatory matters, and intellectual property strategy.
Mary Beth Schornak is Finance Director at Bitterroot. She has more than 15 years of finance and accounting experience supporting life sciences companies and previously served as a Controller at Faraday Pharmaceuticals.
Bitterroot Bio is pioneering the emerging field of cardio-immunology, which investigates the interplay between the immune system and cardiovascular health.
